Analysis of Biomarkers in Patients With Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation Treated With Menin Inhibition.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07627568

Acronym

AML_MenALLO

Enrollment

Registered

2026-06-04

Start date

2026-05-30

Completion date

2027-05-30

Last updated

2026-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia

Keywords

acute myeloid leukemia, alloegeneic stem cell transplantation, menin inhibitor

Brief summary

The white blood cells of patients with acute myeloid leukemia that have undergone allogeneic stem cell transplantation will be investigated. These are patient where the leukemia has returned after the transplantation.

Detailed description

The study will investigate biomarkers including humen endogenous retrovirus expression and T cell phenotypic analysis in patients with AML with NPM1 mutations or KMT2A rearrangements. These biomarkers have been previously described: Blood. 2026 Jan 29;147(5):584-601. doi: 10.1182/blood.2025029712. PMID: 41144759

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of acute myeloid leukemia with NPM1 mutations or KMT2A rearrangements * Hematological relapse after allo-HCT * 18 years or older

Exclusion criteria

* no signed informed consent

Design outcomes

Primary

Measure	Time frame	Description
Correlative biomarker	1 year	HERV expression by AML cells
Biomarkers will be correlated with survival and leukemia response	may 2026 till may 2027	The biomarkers HERV, HLA class I and II, T cell phenotype

Countries

Germany

Contacts

CONTACTRobert Zeiser, MD

robert.zeiser@uniklinik-freiburg.de+4976127034020

Outcome results